Source: Annual Congress 2012 - Prognosis of lung cancer
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
B.Y. Lee, M.A. Kim, J.C. Lee, Y.S. Park, H.R. Kim, C.M. Choi (Seoul, Republic Of Korea). Clinical implication of stem cell markers in N2 positive non-small cell lung cancer. Eur Respir J 2012; 40: Suppl. 56, 4165

Member's Comments

No comment yet.

Related content which might interest you: Clinical characterization of non-small cell lung cancer tumors showing neuroendocrine differentiation Source: Eur Respir J 2002; 20: Suppl. 38, 270s Year: 2002 The impact of neuroendocrine differentiation in the prognosis of non-small cell lung cancer Source: Annual Congress 2012 - Prognosis of lung cancer Year: 2012 Soluble non-invasive markers in non-small cell lung cancer Source: Eur Respir J 2005; 26: Suppl. 49, 459s Year: 2005 Clinical features of nonsmall cell lung cancer cases Source: Eur Respir J 2002; 20: Suppl. 38, 75s Year: 2002 Expression of βig-h3 as a marker of local tumor invasion in non-small cell lung cancer Source: Eur Respir J 2006; 28: Suppl. 50, 770s Year: 2006 CHD4 is associated with poor prognosis of non-small cell lung cancer patients through promoting tumor cell proliferation Source: International Congress 2016 – Prognostic variables in lung cancer I Year: 2016 Are there any peculiarities in tumour behavior and different tumour markers expression in nonsmall cell lung cancer? Source: Eur Respir J 2001; 18: Suppl. 33, 232s Year: 2001 Neuroendocrine differentiation as a prognostic factor in non-small cell lung cancer Source: Eur Respir J 2007; 30: Suppl. 51, 669s Year: 2007 Ki-67 in non-small cell lung cancer Source: Annual Congress 2012 - New results in molecular pathology and functional genomics of neoplastic and non-neoplastic lung disease Year: 2012 Clinical significance and functional roles of FoxM1 in non-small cell lung cancer Source: Annual Congress 2012 - New biomarkers for lung cancer Year: 2012 Second line therapy for advanced non-small cell lung cancer Source: European Multidisciplinary Conference in Thoracic Oncology 2009 Year: 2009 A non-small cell lung cancer modelling by endogenous κ-ras manipulation Source: Annual Congress 2005 - Pathophysiology of lung cancer progression: impact in diagnosis and early detection Year: 2005 The expression of central cell cycle regulators in non-small cell lung cancer has therapy-dependent prognostic impact Source: Annual Congress 2012 - New results in molecular pathology and functional genomics of neoplastic and non-neoplastic lung disease Year: 2012 Nuclear survivin in pN2 nonsmall cell lung cancer: prognostic and clinical implications Source: Eur Respir J 2009; 33: 127-133 Year: 2009 PD-L1 determination in cytological and histological samples in patients with non-small cell lung cancer Source: International Congress 2018 – Linear and radial EBUS and peripheral nodules Year: 2018 The influence of erythropoietin on growth and survival in non-small cell lung cancer cell lines Source: International Congress 2015 – Cell biology of lung cancer and new biomarkers Year: 2015 Prognostic and potential therapeutic impact of prostate specific membrane antigen expression in non-small cell lung cancer Source: International Congress 2018 – Lung cancer: novel prognostic markers and scores Year: 2018 Different expression of miRNA in non-small cell lung cancer according to its clinical stage Source: Annual Congress 2008 - Novel mechanisms and targets of molecular pulmonary pathology Year: 2008 Biological therapies in nonsmall cell lung cancer Source: Eur Respir J , 49 (3) 1601520; DOI: 10.1183/13993003.01520-2016 Year: 2017